Welcome to our dedicated page for Relay Therapeutics SEC filings (Ticker: RLAY), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Parsing a biotech filing that details molecular dynamics, R&D burn rates and clinical milestones is tough. Relay Therapeutics’ disclosures are no exception—its 10-K alone weaves through protein-motion science, cash runway assumptions and partnership revenue streams. If you’ve ever asked, “How do I read the Relay Therapeutics annual report 10-K simplified?” or searched for “Relay Therapeutics SEC filings explained simply,” this page is built for you.
Stock Titan’s AI-powered summaries extract the datapoints that matter—trial timelines, collaboration payments and segment expenses—so you can stop scrolling and start understanding. The platform flags every Relay Therapeutics quarterly earnings report 10-Q filing the moment it appears on EDGAR, then pairs it with plain-English context and historical comparisons. Material news? Our engine decodes each Relay Therapeutics 8-K material events explained entry, highlighting how new data or partnerships may affect valuation.
Need to monitor executive sentiment? Real-time alerts surface Relay Therapeutics Form 4 insider transactions real-time, letting you track “Relay Therapeutics insider trading Form 4 transactions” or dive deeper into “Relay Therapeutics executive stock transactions Form 4.” You’ll also find the latest proxy statement executive compensation tables—ideal when searching “Relay Therapeutics proxy statement executive compensation.”
Whether you’re modeling cash needs, assessing pipeline catalysts, or simply understanding Relay Therapeutics SEC documents with AI, every filing type is here, updated instantly and translated into actionable insight. Skip the 300-page PDFs; access Relay Therapeutics earnings report filing analysis, compare NDA-ready candidates across periods, and follow the disclosures that drive this precision-medicine leader forward.
Relay Therapeutics (RLAY) insider transaction: The Chief Corporate Development Officer reported sales of common stock primarily to cover taxes from recent RSU vesting. On October 28, 2025, 19,135 shares were sold at $7.29. On October 29, 2025, 21,394 shares were sold at a weighted average price of $7.50, with trade prices ranging from $7.49 to $7.52.
The sale on October 28, 2025 was to satisfy income tax withholding upon the vesting of 47,897 RSUs on October 27, 2025, and the reporting person had no discretion over that transaction. Following these sales, the reporting person beneficially owns 337,469 shares, which include 108,919 shares underlying RSUs.
Relay Therapeutics (RLAY) reported an insider transaction by its Chief Financial Officer. The CFO sold 21,664 shares of common stock at $7.29 on October 28, 2025. The filing states the sale was to cover income tax withholding tied to the vesting of 48,115 RSUs on October 27, 2025, and the officer had no discretion over the sale under company policy. Following the transaction, the officer beneficially owned 313,631 shares, which includes 110,008 shares underlying RSUs.
Relay Therapeutics (RLAY) officer reports Form 4 transaction. On 10/28/2025, the President, R&D sold 30,897 shares of common stock at $7.29 per share. The filing states the sale was made to cover income tax withholding obligations tied to the vesting of 68,622 RSUs on October 27, 2025, and the reporting person had no discretion over the transaction under company policies.
Following the transaction, the officer beneficially owned 521,823 shares, held directly. This total includes 168,866 shares underlying RSUs.
Commodore Capital and related filers reported beneficial ownership of 13,350,000 shares of Relay Therapeutics (RLAY), representing 7.8% of the outstanding common stock as of June 30, 2025. The Schedule 13G/A names Commodore Capital LP, Commodore Capital Master LP, and managing partners Michael Kramarz and Robert Egen Atkinson as joint filers. The Firm acts as investment manager to Commodore Capital Master LP and the managing partners exercise investment discretion. The filing states the position was not acquired to change or influence control and attaches a Joint Filing Agreement.
Point72-related filers reported a 7.8% stake in Relay Therapeutics (RLAY). The Schedule 13G/A shows Point72 Asset Management, Point72 Capital Advisors and Steven A. Cohen collectively report shared voting and dispositive power over 13,445,704 shares of Relay common stock as of the close of business on June 30, 2025. The shares are held through Point72 Associates, an investment fund managed by Point72 Asset Management, and Cubist Systematic Strategies, LLC acted as a sub-advisor for a portion of the holdings. The filing includes a certification that the position was not acquired to influence control of the issuer.
FAQ
What is the current stock price of Relay Therapeutics (RLAY)?
What is the market cap of Relay Therapeutics (RLAY)?
